1 / 14

Giant Cell Tumor of Bone (GCTB)

Denosumab Safety and Efficacy in Giant Cell Tumor of Bone (GCTB): Interim Results From a Phase 2 study.

tyrone-mooney
Télécharger la présentation

Giant Cell Tumor of Bone (GCTB)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Denosumab Safety and Efficacy in Giant Cell Tumor of Bone (GCTB): Interim Results From a Phase 2 study Sant Chawla,1 Jean-Yves Blay,2 Javier Martin Broto,3Edwin Choy,4 Martin Dominkus,5 Jacob Engellau,6Robert Grimer,7 Robert Henshaw,8 Emanuela Palmerini,9Peter Reichardt,10 Piotr Rutkowski,11 Keith Skubitz,12David Thomas,13 Yufan Zhao,14 Yi Qian,14 Ira Jacobs14 1Sarcoma Oncology Center, Santa Monica, CA, USA; 2University Claude Bernard Lyon I, Centre Léon Bérard, Department of Medicine, Lyon, France; 3Hospital Son Dureta, Palma de Mallorca, Spain; 4Dana Farber/Harvard Cancer Center, Massachusetts General Hospital, Boston, MA, USA; 5Medizinische Universitaet Wien, Vienna, Austria; 6Skåne Universitetssjukhus, Lund, Sweden; 7Royal Orthopaedic Hospital, Birmingham, UK; 8Georgetown University College of Medicine, Washington, DC, USA; 9Istituti Ortopedici Rizzoli, Bologna, Italy; 10HELIOS Klinik Bad Saarow, Bad Saarow, Germany; 11Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warszawa, Poland; 12Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; 13Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; 14Amgen Inc., Thousand Oaks, CA, USA

  2. Giant Cell Tumor of Bone (GCTB) • Aggressive, primary osteolytic tumor • Causes local pain and impairs mobility and function1 • No approved or effective medical therapy • Surgical intervention often associated with significant morbidity2 • Mendenhall WM et al. Am J Clin Oncol. 2006;29:96–9. • Balke M et al. J Cancer Res Clin Oncol. 2009;135:149–58.

  3. RANK and RANKL in Giant Cell Tumor of Bone • Tumors contain osteoclast-like giant cells expressing RANK and stromal cells expressing RANK ligand (RANKL), a key mediator of osteoclast formation, activation, function, and survival.1-4 • Excessive RANKL secretion causes an imbalance in bone remodeling in favor of bone breakdown.5-7 RANK expression in GCTB8 1. Atkins GJ, et al. J Bone Miner Res. 2006; 21:1339–49. 2 Huang L, et al. Am J Pathol. 2000;156:761–7. 3. Kartsogiannis V, et al. Bone. 1999;25: 525–34. 4. Roux S, et al. Am J Clin Pathol. 2002; 117:210–6. 5. Burgess TL, et al. J Cell Biol. 1999;145:527–38. 6 Lacey DL, et al. Cell. 1998;93:165–76. 7. Yasuda H, et al. Proc Natl Acad Sci USA. 1998;95:3597–602. 8. Bekker PJ et al. J Bone Miner Res. 2004;19:1059–66. RANKL expression in GCTB8

  4. Activated Osteoclast Precursor Activated Giant Cell Osteoclast Fusion RANKL is a Central Mediator of Bone Destruction in Giant Cell Tumor of Bone RANK RANK RANKL RANKL Osteoclast Precursors Stromal Cellsof GCTB

  5. Denosumab in Giant Cell Tumor of Bone • Fully human monoclonal antibody that binds to RANKL1 • Inhibits osteoclast-mediated bone destruction • Initial open-label, proof-of-concept, phase 2 study of denosumab in GCTB (N = 37):2 • Tumor response in 86% of patients with GCTB • Clinical benefit in 84% of patients (reduced pain or improvement in functional status per investigator) • No serious treatment-related adverse events • Bekker PJ et al. J Bone Miner Res. 2004;19:1059–66. • Thomas D et al. Lancet Oncol. 2010;11:275–80.

  6. Phase 2 Follow-on Study: Interim Analysis Day Month 1 8 15 2 3 4 5 6 Months 7– N Denosumab 120 mg sc Adults or skeletally mature adolescents with GCTB • Cohort 2: Salvageable GCTB, surgery planned • Safety • Surgery: delay, avoidance, or reduced morbidity • Cohort 1: Surgically unsalvageable GCTB • Safety • Disease progression (investigators’ assessment) SC: subcutaneous

  7. ResultsSubject Demographics and Disease Characteristics N = All enrolled subjects

  8. Safety ResultsDenosumab Exposure and Adverse Events * N = number of subjects who received at least 1 dose of denosumab

  9. Efficacy Response per Investigator AssessmentNo Disease Progression in the Majority of Subjects Cohort 1: Surgically Unsalvageable N = 73* Cohort 2: Salvageable, Surgery Planned N = 23* 38 (52%) 1 (1%) 2 (3%) * N = the number of subjects who received denosumab, had the opportunity to be on study for ≥6 months, and had disease progression data at the time of analysis. The disease response data analysis was based on the best response reported during the assessment period.

  10. Efficacy: Cohort 2At 12 Months, Most Subjects in Cohort 2 Had No Surgery or a Less Morbid Surgical Procedure Than Planned * In order from most morbid to least morbid † Other planned skeletal procedures included replacement of proximal tibia, sacral lesion/bone resection, and pelvic resection (1 each).

  11. Results – Efficacy 36-year-old man with GCTB and severe pain, left lower extremity After 29 weeks of denosumab treatment Baseline

  12. Pre-Treatment (August 2009) Courtesy of Alexander Fedenko, MD and Elke Ahlmann, MD (USC)

  13. Post-Treatment (Limb Salvage, September 2011) Courtesy of Alexander Fedenko, MD and Elke Ahlmann, MD (USC)

  14. Summary • Denosumab was well tolerated by these subjects with GCTB; no new risks were observed in this population • ONJ, a known risk with denosumab, was observed at a low rate consistent with that seen in other studies • Disease progression was halted in 99% of subjects • Of 23 subjects for whom surgery was planned: • 15 had no surgery • 8 had less morbid surgeries than planned • This study is ongoing; denosumab continues to be studied as a potential treatment for GCTB

More Related